Vaccine for coeliac disease enters phase 2 trial

A phase 2 randomised controlled study of the therapeutic vaccine Nexvax2® is underway in Australian and New Zealand adults with HLA-DQ2·5 genotype positive coeliac disease. The epitope-specific immunotherapy which ‘reprograms’ T cells, suppresses inflammation and aims to increase the threshold for clinical reactivity to gluten in patients with coeliac disease. It offers patients the promise of ...

Already a member?

Login to keep reading.

© 2021 the limbic